Risk adjusted net present value: What is the current valuation of Johnson & Johnson’s Nipocalimab?

Nipocalimab is a monoclonal antibody commercialized by Johnson & Johnson, with a leading Phase III program in Acquired (Autoimmune) Hemolytic Anemia.

Source link
#Risk #adjusted #net #present #current #valuation #Johnson #amp #Johnsons #Nipocalimab